Drugmaker in Japan seeks approval for stem cell treatment for Parkinson's
The drugmaker applied to Japanese regulators for manufacturing and marketing authorization aimed at treating patients with advanced Parkinson's disease, it said in a statement.
A trial led by Kyoto University researchers indicated that the company's treatment using induced Pluripotent Stem (iPS) cells — which have the potential to develop into any cell in the body — was safe and successful in improving symptoms.
The study involved seven Parkinson's patients between 50 and 69 years old, with each receiving a total of either 5 million or 10 million cells implanted on both sides of the brain.
The iPS cells from healthy donors were developed into the precursors of dopamine-producing brain cells, which are no longer present in people with Parkinson's disease.
The patients were monitored for two years, and no major adverse effects were found, the study said. Four patients showed improvements in symptoms, it said.
The trial results were published in Nature in April.
Sumitomo Pharma is also carrying out a clinical trial in the United States.
Parkinson's disease is a chronic, degenerative neurological disorder that affects the body's motor system, often causing shaking and other difficulties in movement.
Worldwide, about 10 million people have the illness, according to the Parkinson's Disease Foundation.
Currently available therapies "improve symptoms without slowing or halting the disease progression," the foundation said.
iPS cells are created by stimulating mature, already specialized, cells back into a juvenile state — basically cloning without the need for an embryo.
The cells can be transformed into a range of different types of cells, and their use is a key sector of medical research.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Times
an hour ago
- Japan Times
Japan approves price cut for Alzheimer's drug Lecanemab
A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai and U.S. industry peer Biogen, by 15% in Japan starting Nov. 1. The decision is based on an assessment by the Central Social Insurance Medical Council that cited the low cost-effectiveness of the drug used to treat dementia caused by Alzheimer's disease. The price of the drug will be lowered to ¥97,277 for a 500-milligram bottle. Dosages are based on weight. For example, a patient weighing 50 kilograms would see an annual cost reduction from about ¥2.98 million to about ¥2.53 million. Lecanemab is said to be innovative because it removes abnormal proteins that accumulate in patients' brains, and it is expected to slow the progression of the disease. The medication was subject to a system that adjusts drug prices based on cost-effectiveness for high-priced or large-market drugs. At a meeting in July, the council described Lecanemab as having low cost-effectiveness compared with existing treatments.
Yomiuri Shimbun
an hour ago
- Yomiuri Shimbun
Researchers Find Link between Gene, Pancreatic Cancer Malignancy
KYOTO (Jiji Press) — Researchers mainly from Kyoto University have found that impaired function of a specific gene contributes to the malignancy of pancreatic cancer, which is hard to treat with chemotherapy. They said that the reduced gene function increases a protein that promotes metastasis and that existing drugs may be effective in suppressing the protein's functions. The finding was published in the Journal of Clinical Investigation in June. Pancreatic cancer is the third leading cause of cancer death in Japan. The five-year survival rate is 8.5%, the worst among any cancer. Malignant cases account for 30% to 40%, but the underlying mechanisms had not been well understood. The team examined pancreatic cancer tissue removed during surgery and found that the decline in function of Polybromo 1, or PBRM1, a gene that regulates the expression of various proteins, is linked to greater malignancy and a higher risk of relapse. A genetic modification to disable PBRM1 in mice with pancreatic cancer resulted in a higher malignancy rate, increased metastases and shorter survival. The cancer cells showed an increased level of vimentin, a protein that promotes metastasis. Meanwhile, the malignancy rate and metastases decreased after mice were given a drug that suppresses vimentin. Such correlations were also confirmed in human pancreatic cancer. The research 'has shown that drugs to suppress vimentin effects may lead to a new treatment for highly malignant pancreatic cancer,' Kyoto University associate professor Akihisa Fukuda said. 'We hope to conduct clinical trials to realize early practical application.'
NHK
a day ago
- NHK
African forest elephant gives birth at Japanese zoo
An African forest elephant has given birth at a zoo in the Japanese city of Hiroshima. This is the first time an elephant of this endangered species has been born in Japan. Officials at Asa Zoological Park say the elephant, called May, gave birth to a baby shortly before 5 a.m. on Tuesday. The officials say the calf was smaller than expected, measuring about 75 centimeters at the highest point on its back. They add its gender is not yet known. The baby elephant was seen walking and trying to suckle. But it could not reach its mother's breast, so zookeepers have piled up straw on the floor to help it. The mother was also seen caring for the baby, touching it with her trunk. African forest elephants inhabit forest areas in Africa and have oval-shaped ears. There are only two in Japan -- May, a female, and Dai, a male. Both live in Asa Zoo. The zoo has been working to breed the pair. Last summer, it confirmed May's pregnancy, the first of this species in Japan. A woman in her 60s from Hiroshima said she is very happy about the birth and looks forward to seeing May and her baby playing together. Zoo director Abe Katsuhiko said he is relieved that the mother and baby are in good health. He added the zoo will closely monitor the baby's growth and ensure it does not get injured. The zoo says it will decide when visitors will be allowed to see the elephants by taking into account factors such as their health condition.
